SEC Form 4 · accession 0001437749-16-034509
Sun BioPharma, Inc. · SNBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David B Kaysen
Officer — President and CEO · Director
Period of report
Jun 24, 2016
Accepted (ET)
Jun 28, 2016 · 12:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001029125
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 24, 2016 | P$0 | 50,000 | — | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F1 | $1.50 | Jun 24, 2016 | P | 25,000 | A | Jun 24, 2016 | Jun 24, 2021 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Reported securities purchased as one share of common stock and one warrant to purchase one-half share of common stock for a combined price of $1.00 per "unit."